跳至主要内容
临床试验/CTRI/2025/12/099695
CTRI/2025/12/099695尚未招募2/3 期

A Randomized Controlled Clinical Study to evaluate the efficacy of Vamshapatra Kwatha in Artavakshaya

Dr Kavya M Rao1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2026年1月3日最近更新:

试验速览

阶段
2/3 期
状态
尚未招募
发起方
入组人数
40
试验地点
1

研究概览

简要总结

Normal menstruation is an essential physiological function of women during their reproductive age and is indicator of healthy reproductive organ. Artavakshaya is when there is scanty bleeding or when the menstrual bleeding occurs more than 35 days apart and which remains constant at that frequency.In Adarsha Nighantu Uttararda under Trunadivarga Vamshapatra kwatha mentioned as Artavajanaka will be brought under trial in comparison with krishnatila kwatha which is proved to be effective in artavakshaya. It has the drug which contains artavajanana shotaghna raktavikara nashana actions. After fulfilling the assessment criteria, subjects will be divided into 2 groups and the intervention will be given. The intervention group will be given Vamshapatra kwatha and the comparative group will be given Krishna tila kwatha.

The treatment period will be 2 consecutive cycles, assessment will be done on the 5th day of each cycle during the treatment and follow up will be done on 5th day of cycle.

Hypothesis of this study H0 there is neither statistically significant difference between Vamshapatra kwatha and Krishnatila kwatha nor vamshapatra kwatha is better than Krishnatila kwatha in Artavakshaya

H1  there is statistically significant difference between Vamshapatra kwatha and Krishnatila kwatha with Vamshapatra kwatha showing better effect than Krishnatila kwatha in Artavakshaya

研究设计

研究类型
Interventional
分配方式
Coin toss, Lottery, toss of dice, shuffling cards etc
盲法
None

入排标准

年龄范围
16.00 Year(s) 至 35.00 Year(s)(—)
性别
Female

入选标准

  • Women aged between 16 to 35 years Patients with history of artavakshaya in atleast 2 previous cycle Yathochitakala adarshanam of artava the interval between 2 cycles exceeds more than 35 days Haemoglobin greater than 11 gm per dl.

排除标准

  • Patients suffering from any systemic diseases Pregnant woman and lactating mother Known case of HIV and HBsAg positive Endometrial or cervical or breast carcinoma or any malignant diseases Thyroid disorders Female using oral contraceptives IUCD injectable contraceptives Any congenital anomalies.

研究者

发起方
Dr Kavya M Rao
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Dr Kavya M Rao

Alvas Ayurveda Medical College

研究点 (1)

Loading locations...

相似试验